Replies to post #13530 on GTC Biotherapeutics (fka GTCB)

[stockdak]

Thanks for that info DD. I did not realize that.

I am not sure if a FOB deal upfront of $10+ million is realistic or not.

The best candidate for a larger upfront might be CD-137 as other anti-cancer mabs deals that I recall have brought in large upfront payments. They have never indicated partnership interest in CD-137 though have they?

As you said in the next 3 months something has to happen. I would take the buyout and be happy at $1.5 to $2. As much as Atryn may have promise in many ailments they are a long way down the road except for HD and DIC.